By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


Company News
Hemispherx (HEB) Announces Completion Of Ampligen Manufacturing Technology Transfer Milestone 10/19/2016 7:51:15 AM
Hemispherx (HEB) Announces Granting Of Final Settlement Of Derivative And Class Action Case 9/22/2016 10:10:41 AM
Hemispherx (HEB) Regains Compliance With NYSE MKT Continued Listing Standards 9/19/2016 7:55:01 AM
Hemispherx (HEB) To Present At The 18th Annual Rodman & Renshaw Global Investment Conference 9/6/2016 8:38:15 AM
Hemispherx (HEB) Announces $5 Million Registered Direct Offering 8/31/2016 8:01:18 AM
Hemispherx (HEB) Announces Major Breakthrough: Approval For Commercial Sale Of Rintatolimod (U.S. Tradename: Ampligen) To Treat Severe Cases Of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) In The Argentine Republic 8/23/2016 8:02:03 AM
Hemispherx (HEB) Forms Scientific Advisory Board To Provide Additional Scientific And Pharmaceutical Expertise 8/19/2016 6:49:56 AM
Hemispherx (HEB) Announces 1-for-12 Reverse Stock Split 8/18/2016 7:39:27 AM
Hemispherx (HEB) Announces Financial Results For The Six Months Ended June 30, 2016 8/16/2016 9:20:03 AM
Hemispherx (HEB) Conducts An Interview With The Wall Street Transcript 8/16/2016 9:08:44 AM